title: Impact of preepiglottic space tumor involvement on concurrent chemoradiation therapy.
abstract: OBJECTIVE
  The aim of the study was to determine the prognostic impact of preepiglottic space (PES) involvement on local failure after concurrent chemoradiation therapy for squamous cell carcinoma.
  
  
  METHODS
  Retrospective chart review of patients who underwent concurrent chemoradiation therapy for T3 or T4 laryngeal, T4 hypopharyngeal, and T3 or T4 oropharyngeal squamous cell carcinoma were eligible for inclusion. Patients were then stratified by the presence or absence of PES tumor involvement. A multivariate analysis was performed on the presence of recurrence using the following pretreatment variables: PES involvement, tumor extent, pathologic cell differentiation, lymph node involvement, age, and sex.
  
  
  RESULTS
  A total of 102 patients were included in the study. Twenty-seven (28%) patients had documented PES involvement. Mean follow-up for all patients was 46 months. Involvement of the PES was not significantly associated with local tumor persistence or recurrence (P = .69). No other variables significantly impacted tumor recurrence.
  
  
  CONCLUSIONS
  Preepiglottic space involvement does not negatively impact local tumor control after concurrent chemoradiation therapy.
authors.affiliation: Division of Otolaryngology-Head and Neck Surgery, Duke University Medical Center, Durham, NC 27710, USA. walter.lee@duke.edu
authors.forename: Walter T
authors.initials: WT
authors.lastname: Lee
authors.forename: Mark
authors.initials: M
authors.lastname: Rizzi
authors.forename: Joseph
authors.initials: J
authors.lastname: Scharpf
authors.forename: Robert R
authors.initials: RR
authors.lastname: Lorenz
authors.forename: Jerrod P
authors.initials: JP
authors.lastname: Saxton
authors.forename: David J
authors.initials: DJ
authors.lastname: Adelstein
authors.forename: Ramon M
authors.initials: RM
authors.lastname: Esclamado
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D003131:Combined Modality Therapy; D004825:Epiglottis / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies